In new study led by @bblarsen1 in collab w @veeslerlab @VUMC_Vaccines we map functional & antigenic landscape of Nipah virus receptor binding protein (RBP)
Results elucidate constraints on RBP function & provide insight re protein’s evolutionary potentialbiorxiv.org/content/10.110…
Nipah is bat virus that sporadically infects humans w high (~70%) fatality rate. Has been limited human transmission
Like other paramyxoviruses, Nipah uses two proteins to enter cells: RBP binds receptor & then triggers fusion (F) protein by process that is not fully understood
RBP forms tetramer in which 4 constituent monomers (which are all identical in sequence) adopt 3 distinct conformations
RBP binds to two receptors, EFNB2 & EFNB3
RBP’s affinity for EFNB2 is very high (~0.1 nM, over an order of magnitude higher than SARSCoV2’s affinity for ACE2)
To study mutants of RBP, we used pseudovirus deep mutational scanning, which uses non-replicative lentivirions safe at BSL-2 ()
We generated pseudoviruses w all amino-acid mutants of RBP & quantified their ability to infect cells expressing EFNB2 or EFNB3 blog.addgene.org/viral-vectors-…
To ensure these safe pseudovirus experiments generated beneficial knowledge about RBP function & antigenicity but *not* potentially hazardous info () on mutations that adapt RBP to human receptors, we used cells expressing bat rather than human EFNs pubmed.ncbi.nlm.nih.gov/30419157/
Figure below shows how all amino-acid mutations to RBP affect pseudovirus entry into cells expressing bat EFNB3.
Some regions of RBP quite tolerant of mutations, but others under heavy constraint (most mutations disrupt pseudovirus cell entry)
Constraint especially high in dimerization faces & sites in neck that likely play key role in triggering F (see paper for details on specific sites)
We also measured how all functionally tolerated RBP mutations affect binding to EFNB2 vs EFNB3, & identified specific mutations that increase binding to both or just one of the bat versions of these receptors
We also measured how all RBP mutations affect neutralization by panel of antibodies.
Some antibodies (eg, nAH1.3) are escaped by many well-tolerated mutations, whereas others (eg, HENV-103) are mostly escaped only by mutations that impair RBP function.
The above finding is informative for helping select antibodies that are likely to be resistant to viral escape. However, it is notable that antigenic diversity of known Nipah viruses is low, with almost none of the escape mutations observed among natural sequences.
Overall, this study generates a huge wealth of information for understanding RBP function, receptor binding, antigenicity, and evolution.
@bblarsen1 has made a superb webpage with interactive plots that facilitate exploration of the data: dms-vep.org/Nipah_Malaysia…
Thanks to everyone who contributed to this study: @bblarsen1, Teagan McMahon, Jack Brown, Zhaoqian Wang, @CaelanRadford, @VUMC_Vaccines, and @veeslerlab
Over 4 yrs after being first to publicly release SARS-CoV-2 genome, Yong-Zhen Zhang just published large set of viral seqs from first stage of COVID-19 outbreak in China
Zhang recruited nearly all COVID-19 patients hospitalized at Shanghai Public Health Center in first 2/3 (Jan-Sep) of 2020.
The largest source of Shanghai patients in Jan/Feb 2020 was imported cases from Wuhan or elsewhere in Hubei, thereby providing window into Wuhan outbreak.
Overall, Zhang obtained 343 near-full-length SARS-CoV-2 sequences from 226 distinct patients, including 133 sequences from samples collected no later than Feb-15-2020.
A phylogenetic tree showing these sequences is below.
In new study led by Caleb Carr & @khdcrawford, we measure how all mutation to Lassa virus glycoprotein complex (GPC) affect cell entry & antibody escape
Results show how prospective assessment of effects of mutations can inform design of countermeasures biorxiv.org/content/10.110…
As background, Lassa virus causes of thousands of deaths each year, mostly from spillovers from its rodent host, but there is occasional human-to-human transmission.
Lassa is biosafety-level-4 priority pathogen, & efforts are underway to develop vaccines & antibody therapeutics.
We used pseudovirus deep mutational scanning to study effects of nearly all 9,820 amino-acid mutations to Lassa’s GPC at biosafety-level-2 by making genotype-phenotype linked libraries of lentiviral pseudotypes blog.addgene.org/viral-vectors-…
Here is my brief analysis of Dec-28-2019 SARSCoV2 submission to Genbank.
This analysis supports my conclusion to WSJ () that this submission does not tell origin of virus, but does show sequence known to Chinese Academy of Sciences weeks before released wsj.com/politics/natio…
Here is link to my full analysis:
See also images of the same posted below (although it's probably just easier to click on link above and read HTML). github.com/jbloom/SARS2_2…
I also don't think Genbank/NCBI could have reasonably known at time that this sequence was so valuable given that Chinese govt did not announce they had sequence or had submitted it, and Genbank receives vast numbers of submissions.
As background, human influenza constantly evolving. So people exposed to different strains, depending on their age & idiosyncratic history of infection/vaccination.
Different exposure histories cause people to make antibodies w different specificities
I wanted to highlight this pre-print by David Ho’s group on the neutralizing antibody response to new (XBB.1.5-based) COVID vaccine booster, as it illustrates some points related to paradigm of updating SARS-CoV-2 vaccines to keep pace w viral evolution. biorxiv.org/content/10.110…
Recall original COVID vaccines worked very well against early SARS-CoV-2 strains
Unfortunately, virus has been evolving, so antibodies elicited by that vaccine don’t neutralize newer viral variants very well
We made spike pseudovirus deep mutational scanning libraries of mutations across XBB.1.5 spike (as well as XBB.1.5 RBD and BA.2 spike libraries).
We used these libraries to measure how >9,000 mutations affected cell entry, ACE2 binding, and serum antibody escape.
To measure how mutations affected ACE2 binding, we leveraged approach previously used by David Ho & @yunlong_cao groups that is based on fact neutralization of spike-mediated entry by soluble ACE2 is proportional to ACE2 binding.